CDKN2A and central nervous system cancer: The use of DL in neuropathology, particularly the development of an image-based prediction of molecular driver workflow (e.g., IDH1/2 mutation status or CDKN2A/B copy number status in low-grade gliomas), may provide accessible tools for pathology labs with limited access to molecular testing.